Dupixent (dupilumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients aged 12 years and older with:

• Uncontrolled severe asthma from 1st April 2021; and

• Severe atopic dermatitis who have failed to respond to optimally prescribed topical treatments from 1st March 2021.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. IL-4 and IL-13 are key and central drivers of type 2 inflammation that plays a central role in allergic and eosinophilic asthma, as well as atopic dermatitis. Dupixent is not an immunosuppressant.

Dupixent is jointly developed by Sanofi and Regeneron under a global collaboration agreement.

Full Product Information is available from Sanofi-Aventis Australia Pty Ltd at www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swpdupix or by contacting 1800 818 806.

Consumer Medicine Information (CMI) is available at www.guildlink.com.au/gc/ws/sw/cmi.cfm?product=swcdupix

Further information is available here:

Consumer Media Release Dupixent Asthma PBS Listing152.05 KB

Medical Media Release Dupixent Asthma PBS Listing149.21 KB

Dupixent® PBS listed for severe atopic dermatitis145.4 KB